HIV Status and COVID-19 Treatment Disparities in the US National Clinical Cohort Collaborative - Summary - MDSpire

HIV Status and COVID-19 Treatment Disparities in the US National Clinical Cohort Collaborative

  • By

  • Emmanuel Nazaire Essam Nkodo

  • Pooja Maheria

  • Eric Hurwitz

  • Alfred Jerrod Anzalone

  • Dongmei Li

  • Jessica Y Islam

  • Jing Sun

  • Cara D Varley

  • Zachary Butzin-Dozier

  • Sandra E Safo

  • Kaylyn Kirksey

  • Shukri A Hassan

  • Marlene Camacho-Rivera

  • Rena C Patel

  • Nada Fadul

  • On behalf of the National Clinical Cohort Collaborative USA

  • January 15, 2026

  • 0 min

Share

Objective:

To investigate disparities in COVID-19 therapeutic prescription among persons with HIV and without HIV, particularly focusing on the intersection with other sociodemographic factors.

Key Findings:
  • Persons with HIV had significantly higher adjusted odds of receiving COVID-19 therapeutics compared to persons without HIV (remdesivir, aOR 1.26 [95% CI: 1.20, 1.33]; nirmatrelvir/ritonavir, aOR 2.86 [95% CI: 2.77, 2.95]).
  • Significant racial/ethnic inequities were observed in therapeutic receipt among persons with HIV.
  • American Indian or Alaskan Native and Hispanic/Latinx persons with HIV had lower prevalence of remdesivir receipt compared to White Non-Hispanic individuals.
  • Black/African American individuals with HIV showed lower prevalence of nirmatrelvir/ritonavir receipt compared to their White counterparts.
Interpretation:

While persons with HIV had higher odds of receiving COVID-19 therapeutics, racial and ethnic disparities in treatment access persist, highlighting systemic inequities in healthcare that require policy attention.

Limitations:
  • The study is retrospective and may be subject to biases inherent in observational data.
  • Data may not fully capture all sociodemographic factors influencing treatment access, including potential confounding variables.
Conclusion:

The findings underscore the need for targeted interventions, such as policy changes and community outreach, to address racial and ethnic disparities in COVID-19 treatment access, particularly for vulnerable populations such as persons with HIV.

Original Source(s)

HIV Status and COVID-19 Treatment Disparities in the US National Clinical Cohort Collaborative

  • by Emmanuel Nazaire Essam Nkodo, Pooja Maheria, Eric Hurwitz, Alfred Jerrod Anzalone, Dongmei Li, Jessica Y Islam, Jing Sun, Cara D Varley, Zachary Butzin-Dozier, Sandra E Safo, Kaylyn Kirksey, Shukri A Hassan, Marlene Camacho-Rivera, Rena C Patel, Nada Fadul, On behalf of the National Clinical Cohort Collaborative USA

  • January 15, 2026

Related Content

MEK1/2 inhibitor ATR-002 reshapes host transcriptome and modulates immune regulatory genes in SARS-CoV-2 infection

Long COVID as a network disorder: a mechanism-anchored framework for biological stratification and therapeutic targeting

Increased anti-nucleocapsid secretory IgA and consumption of complement component 3 in post-COVID syndrome patients